Post-transplant treatment with pegylated interferon alpha-2a and ribavirin achieved SVR in 56% of liver transplant recipients with chronic HCV genotype 4 infection. The combination was relatively safe and exhibited a low rate of treatment withdrawal.
The laparoscopic assessment of donors in LDLT is a safe and acceptable procedure that avoids unnecessary large abdominal incisions and increases the chance of achieving donor safety.
BACKGROUND AND OBJECTIVES:There are few reports on hepatitis C virus genotype 4 (HCV-4) recurrences after orthotopic liver transplantation (OLT). Therefore, we undertook a study to determine the epidemiological, clinical and virological characteristics of patients with biopsy-proven recurrent HCV infection and analyzed the factors that influence recurrent disease severity. We also compared disease recurrence and outcomes between HCV-4 and other genotypes.PATIENTS AND METHODS:All patients who underwent OLT (locally or abroad) for HCV related hepatic cirrhosis from 1991 to 2006 and had recurrent HCV infection were identified. Clinical, laboratory and pathological data before and after OLT were collected and analyzed.RESULTS:Of 116 patients who underwent OLT for hepatitis C, 46 (39.7%) patients satisfied the criteria of recurrent hepatitis C. Twenty-nine (63%) patients were infected with HCV genotype 4. Mean (SD) for age was 54.9 (10.9) years. Nineteen of the HCV genotype 4 patients (65.5%) were males, 21 (72.4%) received deceased donor grafts, and 7 (24.1%) developed ≥1 acute rejection episodes. Pathologically, 7 (24.1%) and 4 (13.8%) patients had inflammation grade 3-4 and fibrosis stage 3-4, respectively. Follow-up biopsy in 9 (31%) HCV genotype 4 patients showed stable, worse and improved fibrosis stage in 5, 2 and 2 patients, respectively. Of the 7 patients in the recurrent HCV group who died, 6 were infected with genotype 4 and 4 of them died of HCV-related disease.CONCLUSION:This analysis suggests that HCV recurrence following OLT in HCV-4 patients is not significantly different from its recurrence for other genotypes.
Recurrent hepatitis C is characterized by a higher rate of fibrosis progression and in almost 30% of the cases lead to graft cirrhosis within 5 years Goal: 1) to investigate the rate of severe HCV recurrence after OLT based in protocol liver biopsies and 2) to investigate decompensation, retrasplantation, and survival rates after severe HCV recurrence Methods: The study included 88 patients (pts) who underwent OLT between 6/95 and 12/09. Inclusion criteria were: recurrent HCV infection after OLT (detectable HCV RNA in serum), follow up ≥ 1 year and annual protocol liver biopsies. Severe recurrence of HCV was defined as fibrosis stage ≥ to F3 in protocol biopsies performed at any time after OLT. Pts with fibrosing cholestatic hepatitis were excluded. Staging of recurrent hepatitis C was assessed with the METAVIR score. Actuarial risk analysis was investigated by Kaplan-Meier Results: based on protocol biopsies HCV recurrence was diagnosed as mild in 60 (68%) and severe in 28 (32%) pts. Mean number of biopsies analyzed were 6±2 biopsies per pts. Actuarial Risk at 1,3 and 5 yrs post OLT for fibrosis stage F3 was 8%, 27%, 32% and for F4 0%, 11% and 23% at the same time periods. Mean time interval between OLT and F3-F4 stage fibrosis was 37±26 months. 36% (10/28) of the pts with severe recurrence experienced decompentation, developing ascitis (100%), spontaneous bacterial peritonitis (30%) and encephalopathy (50%).40% developed esophageal varices, with 3 episodes of varices bleeding. Median time interval from last biopsies to decompensation was 30 (1-98) months. 50% of the pts required re transplantation and pts actuarial survival rate at 1,2,3 yrs were 100%, 71%, 47%. In pts with severe recurrence without decompensation (64%) actuarial survival rate at 1,2,3 years were 100%, 97% and 95% (P=0,0002). Conclusions: 1) Natural history of hepatitis C in inmunossupressed liver transplant recipients is characterized by an accelerated fibrogenesis 2) After 5 years of follow up the actuarial risk of reaching stage 3 fibrosis was 32% and of developing cirrhosis 23% 3) Prevalence of decompensation after severe recurrence was 36% with decrease survival overtime, although the higher rate of retransplantation Disclosure: All authors have declared no conflicts of interest.Inroduction:The use of hepatitis B immunoglobulin (HBIg) and lamivudine resulted in a significant reduction in hepatitis B virus (HBV) recurrence following liver transplantation (LT). The aim of this study was (a) to evaluate the use of lamivudine and/or adefovir in combination with long term intravenous HBIg in preventing disease recurrence and (b) to evaluate the HBV serological markers following LT. METHODS: 111 patients who received a liver transplantation for HBV related cirrhosis and were followed in our center from Jan 1990 to December 2009 were included. With the exception of four patients (transplanted prior to 1993) all patients received combination therapy with nucleos(t)ide analogue and HBIg . Breakthrough infection was defined as a re-emergence of HBVD...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.